{
  "week": "2026-W30",
  "label": "Week 30 \u2014 July 26\u20131, 2026",
  "week_start": "2026-07-26",
  "generated": "2026-07-27",
  "stats": {
    "total_entries": 874,
    "new_this_week": 59,
    "compounds_represented": 7
  },
  "by_compound": {
    "psilocybin": [
      {
        "id": "8fcf866910967b043f04e89dc101da7508077785982bc0dc6f5797cb5b5cbcfc",
        "title": "Time-dependent effects of rapid-acting antidepressants in iPSC-derived neurons from treatment-resistant depression and healthy volunteers.",
        "compound": "psilocybin",
        "type": "phase_2",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-07-24",
        "abstract": "Rapid-acting antidepressants like ketamine and serotonergic psychedelics show promise for treatment-resistant depression (TRD), but the molecular mechanisms that contribute to their therapeutic effects remain unclear.\u2026",
        "outcome_summary": null,
        "doi": "10.1038/s41380-026-03768-0",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42498781/",
        "source": "PubMed",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Investigational treatment for treatment-resistant depression.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "811aa64e3e7048aeb0ffb7f47492e9b655ee9e9c782c6015f428a82a1a40c5bc",
        "title": "Comparing synthetic and biological therapy for the treatment of cluster headache: what is needed and when?",
        "compound": "psilocybin",
        "type": "meta_analysis",
        "institution": null,
        "condition": "cluster_headache",
        "sample_size": null,
        "status": "published",
        "date": "2026-07-23",
        "abstract": "Cluster headache is an extremely painful and severely disabling primary headache disorder that, despite its profound impact on quality of life, remains underdiagnosed and undertreated.\u2026",
        "outcome_summary": null,
        "doi": "10.1080/14737175.2026.2706794",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42493477/",
        "source": "PubMed",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Cluster headache is a chronic pain condition treated with psychedelics.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "5b5dc537701b431a2b50884ebfd4cfb669eaf014f5116bdc41ef6099418b34f7",
        "title": "No evidence for deleterious effects of psilocybin and MDMA on working memory or related neurophysiological activity in a non-clinical population: An uncontrolled exploratory study.",
        "compound": "psilocybin",
        "type": "phase_2",
        "institution": null,
        "condition": "other",
        "sample_size": null,
        "status": "published",
        "date": "2026-07-23",
        "abstract": "Research indicates psychedelics hold therapeutic potential, but possible deleterious effects have been insufficiently examined.\u2026",
        "outcome_summary": null,
        "doi": "10.1177/02698811261464991",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42490582/",
        "source": "PubMed",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Exploratory study on psilocybin/MDMA effects in non-clinical population.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "e04b012df7e1a08b24157dfcdaa15f38ff24e7c9f7f28222d41a52a0e6e87b97",
        "title": "Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder",
        "compound": "psilocybin",
        "type": "phase_2",
        "institution": "Johns Hopkins University",
        "condition": "addiction",
        "sample_size": 0,
        "status": "completed",
        "date": "2027-04-01",
        "abstract": "This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care buprenorphine treatment for Opioid use disorder (OUD).\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT06005662",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Psilocybin for opioid use disorder in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "91dfc6aded1cc039241dc2a5bf3e4189b62c34b847fe57aadc163319059871cb",
        "title": "Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder",
        "compound": "psilocybin",
        "type": "phase_2",
        "institution": "COMPASS Pathways",
        "condition": "PTSD",
        "sample_size": 300,
        "status": "recruiting",
        "date": "2026-09-01",
        "abstract": "The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT07570654",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Psilocybin for PTSD treatment in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "2ce36b6f6856ac3c74fa3e7cb4777aaf04b4b46c3f7360805b1455d089764b2d",
        "title": "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants",
        "compound": "psilocybin",
        "type": "phase_1",
        "institution": "MycoMedica Life Sciences PBC",
        "condition": "other",
        "sample_size": 16,
        "status": "completed",
        "date": "2024-11-08",
        "abstract": "MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT06643637",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Human study of psilocybin for psychiatric conditions.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "8fdc77d3bded1252ca59a796431ba8d53eae5ace2a656a4758b3f0a383fff5a0",
        "title": "Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy",
        "compound": "psilocybin",
        "type": "phase_2",
        "institution": "Kyle Greenway",
        "condition": "depression",
        "sample_size": 16,
        "status": "recruiting",
        "date": "2026-05-01",
        "abstract": "The goal of this pilot clinical trial is to learn whether it is feasible to individually tailor psilocybin-assisted psychotherapy (PAP) for people with treatment-resistant depression (TRD) based on their personal preferences.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT07373535",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Psilocybin for treatment-resistant depression in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "bb24f62caf3fc6464bbc67bdb927e743a10ece67f44cdf0eea9ac6da420c4fcf",
        "title": "Mechanistic Studies of Psilocybin in Headache Disorders",
        "compound": "psilocybin",
        "type": "observational",
        "institution": "Yale University",
        "condition": "cluster_headache",
        "sample_size": 50,
        "status": "recruiting",
        "date": "2025-05-19",
        "abstract": "In previous clinical trial work, the investigators observed lasting reductions in headache burden after limited dosing of psilocybin. This purpose of this study is to examine potential sources for this observed effect.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT06464367",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Psilocybin for chronic headache disorders, mechanistic study.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "2ac0a154b4a9c39627884f49147ffc373202e3530f20058b66afe52c3d709ab7",
        "title": "Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD",
        "compound": "psilocybin",
        "type": "phase_1",
        "institution": "Suzanne \"Sue\" Sisley MD",
        "condition": "PTSD",
        "sample_size": 24,
        "status": "recruiting",
        "date": "2026-02-09",
        "abstract": "This study will examine the safety and preliminary efficacy of psilocybin mushrooms to treat adults with PTSD. Up to 24 participants will take part in this study. Each participant will ingest psilocybin from dried mushrooms in a chocolate formulation.",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT07275970",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Psilocybin for PTSD in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "47c270a69e712a713408918d8bf7cde1694bc002f9be263e333372a3268edecf",
        "title": "A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder",
        "compound": "psilocybin",
        "type": "phase_1",
        "institution": "Cybin IRL Limited",
        "condition": "depression",
        "sample_size": 57,
        "status": "completed",
        "date": "2022-08-02",
        "abstract": "The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in healthy participants with and without major depressive disorder (MDD).",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT05385783",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Psilocybin analog for MDD in healthy participants.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "dd95eebcb78f812f092230be04ffb92b3b51c9ea58f5559e753f6516995d5c48",
        "title": "Psilocybin-assisted Interpersonal Therapy for Depression",
        "compound": "psilocybin",
        "type": "observational",
        "institution": "University of Otago",
        "condition": "depression",
        "sample_size": 5,
        "status": "completed",
        "date": "2023-03-15",
        "abstract": "This is a single-arm, open-label interventional study of psilocybin-assisted interpersonal therapy for treatment resistant depression. 20 participants will be recruited to take part in this 8-week intervention that involves 8 sessions of psychotherapy and 2 doses of psilocybin.",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT05581797",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Psilocybin for treatment resistant depression.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "b5284cb6436b8eb7609dc418c00453af5fab3eb19e35a349077cfbffd658501b",
        "title": "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants",
        "compound": "psilocybin",
        "type": "phase_1",
        "institution": "MycoMedica Life Sciences PBC",
        "condition": "other",
        "sample_size": 24,
        "status": "completed",
        "date": "2024-03-27",
        "abstract": "MLS101 is being developed as a low dose psilocybin, that can be administered to treat various neurological and psychiatric conditions.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT06326606",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Study of psilocybin pharmacokinetics in healthy humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "43248dce14066370622fbc78331c169189e842e1cc87961bc315491c91c3e539",
        "title": "Prophylactic Effects of Psilocybin on Chronic Cluster Headache",
        "compound": "psilocybin",
        "type": "phase_1",
        "institution": "Gitte Moos Knudsen",
        "condition": "cluster_headache",
        "sample_size": 10,
        "status": "completed",
        "date": "2020-01-21",
        "abstract": "The purpose of this study is to investigate the prophylactic effects of psilocybin in chronic cluster headache. Subjects will receive a low dose of psilocybin during 3 sessions spaced by one week.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT04280055",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Psilocybin for chronic cluster headache treatment.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "f57decd9faa36076748a66d293646631101e593309d2bb17f0a3fa9686985e77",
        "title": "Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD",
        "compound": "psilocybin",
        "type": "phase_2",
        "institution": "Beersheva Mental Health Center",
        "condition": "OCD",
        "sample_size": 15,
        "status": "recruiting",
        "date": "2024-11-25",
        "abstract": "Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder characterized by recurrent distressing thoughts and substantial anxiety, accompanied by repetitive behaviors or mental rituals. Individuals with OCD often have diminished quality of life, and functional impairment .\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT04882839",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Psilocybin for severe OCD, a psychiatric indication.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "f8aea3d4312fbc3931b56d915e071d5f2dc64c5ec18c5143837f2d1f6025e9fd",
        "title": "Psilocybin for Treatment-Resistant Depression",
        "compound": "psilocybin",
        "type": "phase_2",
        "institution": "Brain and Cognition Discovery Foundation",
        "condition": "depression",
        "sample_size": 30,
        "status": "completed",
        "date": "2021-11-19",
        "abstract": "The purpose of this study is to see if psilocybin, an investigational drug, is safe and well tolerated. Researchers also want to know if psilocybin can improve symptoms of depression.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT05029466",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Psilocybin for treatment-resistant depression in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "a2438cef74df5edbf776f37536c0994f4766b4b0993afed7bf6f0c3554311dae",
        "title": "Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer",
        "compound": "psilocybin",
        "type": "phase_1",
        "institution": "Gustavo Vazquez",
        "condition": "other",
        "sample_size": 15,
        "status": "recruiting",
        "date": "2026-04-01",
        "abstract": "Demoralization syndrome is frequently present in palliative care and oncology patients. In particular, up to a third of patients diagnosed with cancer will experience demoralization due to their illness.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT06818994",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Psilocybin for demoralization in cancer patients is a psychiatric indication.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "f986e0b29a88a9b2c9f7761b5553b1b03a622cb077226395982660689bc19d74",
        "title": "Psilocybin for the Treatment of Migraine Headache",
        "compound": "psilocybin",
        "type": "phase_1",
        "institution": "Yale University",
        "condition": "cluster_headache",
        "sample_size": 14,
        "status": "completed",
        "date": "2017-11-01",
        "abstract": "The purpose of this study is to investigate the effects of oral psilocybin in migraine headache. Subjects will each receive a dose of placebo and a dose of psilocybin approximately 14 days apart.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT03341689",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Psilocybin for chronic pain (migraine headache) in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "00379de6f1062143033ab63a8f9f1315fa5cd395882618d293a915a74b95e2db",
        "title": "Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry",
        "compound": "psilocybin",
        "type": "phase_2",
        "institution": "Sheppard Pratt",
        "condition": "depression",
        "sample_size": 15,
        "status": "published",
        "date": "2023-12-06",
        "abstract": "The study, which was conducted by Dr Scott Aaronson at Sheppard Pratt, Baltimore, and funded by Compass, investigated the safety and efficacy of a single 25mg dose of COMP360 psilocybin treatment in participants with treatment-resistant bipolar II.\u2026",
        "outcome_summary": "An investigator-initiated open-label study of COMP360 psilocybin treatment in 15 participants with treatment-resistant bipolar II depression showed a significant reduction in depressive symptoms, with 12 participants meeting response criteria and 11 meeting remission criteria. No increase in suicidality, manic symptoms, or unexpected adverse events were reported.",
        "doi": null,
        "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2023/Study-results-of-psilocybin-treatment-in-bipolar-II-depression-published-in-JAMA-Psychiatry/default.aspx",
        "source": "Compass Pathways",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Psilocybin treatment for bipolar II depression in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "5604d19ad72defd52da5e53681f646df17de1611f4e19fcf01aabe169cbab312",
        "title": "COMPASS Pathways receives FDA Breakthrough Therapy designation for psilocybin therapy for treatment-resistant depression",
        "compound": "psilocybin",
        "type": "news",
        "institution": "COMPASS Pathways",
        "condition": "depression",
        "sample_size": null,
        "status": "approved",
        "date": "2018-10-23",
        "abstract": "Dr Robin Carhart-Harris, Head of the Psychedelic Research Group, Imperial College London, said, \u201cIn our 2015 study, we provided psilocybin to 19 patients in a clinical setting, coupled with psychological support, and found promising signals of efficacy and safety as treatment for treatment-resistant depression.\u2026",
        "outcome_summary": "COMPASS Pathways received FDA Breakthrough Therapy designation for its psilocybin therapy for treatment-resistant depression. This designation aims to expedite the development process for this potential new treatment.",
        "doi": null,
        "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2018/COMPASS-Pathways-receives-FDA-Breakthrough-Therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression/default.aspx",
        "source": "Compass Pathways",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "FDA designation for psilocybin therapy for depression",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "0a808ddfa11424f047df209364da8e3aeb56b950a941c6353f3b4dba533a6c47",
        "title": "Magic mushrooms may reshape the brain long after the trip ends",
        "compound": "psilocybin",
        "type": "observational",
        "institution": "University of California - San Francisco",
        "condition": "other",
        "sample_size": 28,
        "status": "published",
        "date": "2026-07-22",
        "abstract": ": A single dose of psilocybin produced measurable changes in brain activity and possible changes in brain structure that lasted for up to a month.\u2026",
        "outcome_summary": "A single dose of psilocybin produced measurable changes in brain activity and possible changes in brain structure that lasted for up to a month. Participants who experienced the greatest increase in flexible, varied brain activity also reported more personal insight and later improvements in well-being.",
        "doi": null,
        "url": "http://www.sciencedaily.com/releases/2026/07/260719040005.htm",
        "source": "General News",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Human study on psilocybin's effects on brain structure and well-being.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "791899c9c90181868d4389368399908affacdc1e7678fb6f3bef4fbf3acf331c",
        "title": "What Does a Dose of Magic Mushrooms Actually Do to Your Brain?",
        "compound": "psilocybin",
        "type": "news",
        "institution": null,
        "condition": "other",
        "sample_size": null,
        "status": "other",
        "date": "2026-07-23",
        "abstract": "# What does a dose of magic mushrooms actually do to your brain? A study has found one single dose of magic mushrooms can transform the brain physically \u2014 with changes lasting as long as a month.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "http://www.averyjournal.com/news/national/what-does-a-dose-of-magic-mushrooms-actually-do-to-your-brain/article_ef0d39fd-79d2-5072-ad1e-8b5f88179092.html",
        "source": "General News",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Human brain changes from psilocybin, a psychedelic treatment.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "57955e7a44fe31437e76f17cbf6bf812e47ff5a0d89fdad3b3aa09ec847bff8f",
        "title": "Psychedelic drugs are showing promise in treating mental health conditions",
        "compound": "psilocybin",
        "type": "news",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "other",
        "date": "2026-07-19",
        "abstract": "(L/R) Former FDA Commissioner Marty Makary, Health and Human Services Secretary Robert F. Kennedy Jr., media personality Joe Rogan, W.\u2026",
        "outcome_summary": "Psychedelic drugs like psilocybin are being studied for their potential to treat mental health conditions such as depression and PTSD. Early research suggests these substances, when used in controlled therapeutic settings, may offer new avenues for treatment.",
        "doi": null,
        "url": "https://www.cnbc.com/2026/07/19/psychedelic-drugs-mental-health.html",
        "source": "General News",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Psychedelics for mental health conditions like depression and PTSD.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      }
    ],
    "mdma": [
      {
        "id": "5d2c254cfe84b29431a6fc21a8874ef7b0caca3319053bde78ce692b7fa5d6db",
        "title": "Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing",
        "compound": "mdma",
        "type": "observational",
        "institution": "University Hospital, Basel, Switzerland",
        "condition": "other",
        "sample_size": 28,
        "status": "completed",
        "date": "2017-02-01",
        "abstract": "The study will test the effect of dopamine, serotonin, and direct 5-HT2A receptor stimulation on empathy, mood perception, and amygdala activity to fearful stimuli.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT03019822",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Investigational treatment of mood and emotion processing.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "fa64c661489fd9876e433f536f113a43d94e5b82f8024b4b301fd5703a13b4a7",
        "title": "Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder",
        "compound": "mdma",
        "type": "phase_2",
        "institution": "Resilient Pharmaceuticals",
        "condition": "PTSD",
        "sample_size": 14,
        "status": "completed",
        "date": "2006-09-13",
        "abstract": "This study will examine MDMA-assisted psychotherapy in individuals aged 18 years or older diagnosed with PTSD, with PTSD symptoms not improving after trying at least one treatment.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT00353938",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "MDMA-assisted psychotherapy for PTSD in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "1ca32816b85bafc888e326e0218cbf371685610a70376aea23fae8cb38a1c596",
        "title": "Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function",
        "compound": "mdma",
        "type": "observational",
        "institution": "University of Chicago",
        "condition": "other",
        "sample_size": 43,
        "status": "completed",
        "date": "2022-05-11",
        "abstract": "To study the effects of MDMA, compared to a prototypical stimulant, on social motivation, social ability, and neural indices of social function in healthy volunteers",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT05379959",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "MDMA effects on social motivation and function in humans",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "a9b1a611bff207020d3c16884410438bea1b6d075fc9e834132f58ae58ae0867",
        "title": "A Phase 2A Trial of DT402 for Autism Spectrum Disorder",
        "compound": "mdma",
        "type": "phase_2",
        "institution": "Definium Therapeutics US, Inc.",
        "condition": "other",
        "sample_size": 20,
        "status": "recruiting",
        "date": "2025-12-03",
        "abstract": "A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum Disorder",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT07303907",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Autism spectrum disorder is a psychiatric indication.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "c58731e10da147b8ec5d175c9279cae4299952b932a38b33617041a4147d29d9",
        "title": "Clinical Trial of MDMA-Assisted Therapy for Military Service Members With Posttraumatic Stress Disorder",
        "compound": "mdma",
        "type": "phase_2",
        "institution": "U.S. Army Medical Research and Development Command",
        "condition": "PTSD",
        "sample_size": 86,
        "status": "recruiting",
        "date": "2026-10-01",
        "abstract": "This study is a Phase 2, randomized, double-blind, active-controlled, two-arm, single-site clinical trial designed to evaluate the safety, tolerability, and feasibility of MDMA-Assisted Therapy (MDMA-AT) for Service Members (Active Duty, Guard, or Reserve) diagnosed with moderate-to-severe Post-Traumatic Stress Disorder (PTSD) within a Military Health System (MHS) setting.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT07704762",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "MDMA-assisted therapy for PTSD in military service members.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "89829ddb97f9ea8f393050f7996d496295f0a1089ec3db00015d4ea06ef623dd",
        "title": "Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls",
        "compound": "mdma",
        "type": "observational",
        "institution": "University Hospital, Basel, Switzerland",
        "condition": "other",
        "sample_size": 40,
        "status": "recruiting",
        "date": "2026-06-01",
        "abstract": "This study is to investigate the physiological mechanism of oxytocin system stimulation using 3,4-methylenedioxymethamphetamine (MDMA) as a physiological tool (acute oxytocin releases), not as a medication.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT07555132",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "MDMA for autism spectrum disorder, mechanism of action",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "9f92d0ccc8ed6d773c8d2ebb81fecb7e3ff69dc592401f143aab4913a39e81bb",
        "title": "The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.",
        "compound": "mdma",
        "type": "phase_1",
        "institution": "Yale University",
        "condition": "PTSD",
        "sample_size": 0,
        "status": "completed",
        "date": "2024-05-01",
        "abstract": "This study aims to investigate the effects of MDMA on prefrontal and amygdala activation, and to explore the relationship between these MDMA-induced neural changes and the acute behavioral effects of the drug in patients with PTSD.",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT03752918",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "MDMA for PTSD, human study on neural and behavioral effects.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      }
    ],
    "ketamine": [
      {
        "id": "fcf3ab79ad5501bbffef784f69dcadf62083083e483def8add4e85793dc96ef6",
        "title": "Quality of life and productivity among esketamine responders in a real-world study in Australia and New Zealand.",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-07-21",
        "abstract": "Treatment-resistant depression (TRD) is associated with severe depression, low quality of life (QoL) and reduced work productivity, which may increase risk of relapse, suicide and suboptimal response to treatment.\u2026",
        "outcome_summary": null,
        "doi": "10.1016/j.jpsychires.2026.07.011",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42501650/",
        "source": "PubMed",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Esketamine for treatment-resistant depression in a real-world study.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "019457cd9994a55bbe224afb12a7fc9c32f75684bcad3a240e335d3cbbf6d5ef",
        "title": "Real-World Effectiveness and Cost-Differential of Intranasal Esketamine Versus Intramuscular Ketamine.",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-07-02",
        "abstract": "This study evaluated whether intramuscular (IM) ketamine is non-inferior to intranasal (IN) esketamine for treatment-resistant depression (TRD) and assessed differences in safety and healthcare costs.\u2026",
        "outcome_summary": null,
        "doi": "10.1176/appi.prcp.20260041",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42500270/",
        "source": "PubMed",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Treatment-resistant depression with esketamine and ketamine.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "57985f545fcc1924a85beba6a5baf05c9841768cd44590b1782501a3ecd59c07",
        "title": "Targeting TLR4/PPAR\u03b1-mediated neuroinflammation in the prefrontal cortex: S-ketamine and S-HNK rapidly alleviate depression-like behaviors.",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-07-21",
        "abstract": "Neuroinflammation, particularly Toll-like receptor 4 (TLR4)-mediated signaling, plays a critical role in the pathophysiology of depression.\u2026",
        "outcome_summary": null,
        "doi": "10.1016/j.jneuroim.2026.579038",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42497468/",
        "source": "PubMed",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "S-ketamine for depression-like behaviors in a preclinical model.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "8dd8eafe8c652133da544dec6748fc2c44052535d0d33e0c5b72476a830abe71",
        "title": "Real-world outcomes of intranasal esketamine and intravenous ketamine induction therapy for treatment-resistant depression in a community clinic: a retrospective cohort study.",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-01-01",
        "abstract": "Intravenous (IV) ketamine and intranasal esketamine are NMDA receptor antagonists used for treatment-resistant depression (TRD). Both have demonstrated efficacy in controlled trials, but observational evidence from real-world community settings is limited.\u2026",
        "outcome_summary": null,
        "doi": "10.3389/fpsyt.2026.1867963",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42494735/",
        "source": "PubMed",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Real-world outcomes for TRD treatment with ketamine/esketamine.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "b6e3408dd326af172c4f82d795add1d5492bd7f37bb2e9fb0088fb07de968938",
        "title": "Treating addiction with an addictive drug: the ketamine paradox revisited.",
        "compound": "ketamine",
        "type": "meta_analysis",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-01-01",
        "abstract": "Substance use disorders (SUDs) and treatment-resistant depression (TRD) remain a major global health challenge, marked by high relapse rates and limited long-term effectiveness of existing treatments.\u2026",
        "outcome_summary": null,
        "doi": "10.3389/fpsyt.2026.1866092",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42494734/",
        "source": "PubMed",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Treating addiction and depression with ketamine.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "89278a13676c0a3282f5ae6d8d228a896b07129a1b59f5d06fe072bf8929aa52",
        "title": "Rapid clinical and EEG microstate changes 24\u202fh after intranasal esketamine in major depressive disorder with suicidal ideation: a prospective paired study.",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-07-23",
        "abstract": "Major depressive disorder (MDD) with suicidal ideation constitutes a psychiatric emergency that requires rapid symptom relief. Intranasal esketamine can reduce depressive symptoms within hours, yet the earliest brain-level correlates of response remain insufficiently characterized.\u2026",
        "outcome_summary": null,
        "doi": "10.1016/j.jad.2026.122307",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42492692/",
        "source": "PubMed",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Esketamine for major depressive disorder with suicidal ideation.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "6033b084c8103acf1f4ca763437f71ecffda3374061af19c8b7c7f1cebbe7d31",
        "title": "Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis.",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": null,
        "condition": "depression",
        "sample_size": null,
        "status": "published",
        "date": "2026-01-01",
        "abstract": "Treatment-resistant depression (TRD) remains a major clinical challenge. Intranasal esketamine, used adjunctively with an oral antidepressant, has been evaluated in randomized trials, but uncertainty persists regarding the magnitude and consistency of benefit, durability, and key harms.\u2026",
        "outcome_summary": null,
        "doi": "10.3389/fpsyt.2026.1774549",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42490943/",
        "source": "PubMed",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Meta-analysis of esketamine for treatment-resistant depression.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "2eb4998a9a5d8d92d2f03ef9e8459ec3206f7684a2f72be9f120c25df9dbfdd8",
        "title": "Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients",
        "compound": "ketamine",
        "type": "observational",
        "institution": "University of Zurich",
        "condition": "depression",
        "sample_size": 100,
        "status": "recruiting",
        "date": "2025-04-01",
        "abstract": "With progression of cancer, patients and their caregivers experience challenging emotional distress, which can make them feel depressed and very anxious. Patients with advanced cancer often do not have long to live.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT06665568",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Ketamine for depression and anxiety in palliative care cancer patients.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "2345aa4b4c6f59e28dd74c57fa85cab3f40f2727b9d77027b1cf629073497412",
        "title": "A Study of Sublingually Administered (S)-Ketamine Oral Solution in Healthy Participants",
        "compound": "ketamine",
        "type": "phase_1",
        "institution": "Janssen Research & Development, LLC",
        "condition": "other",
        "sample_size": 17,
        "status": "completed",
        "date": "2020-02-18",
        "abstract": "The purpose of this study is to characterize the plasma pharmacokinetic (PK) profile following the single ascending dose (SAD) levels of an (S)-ketamine oral solution for sublingual administration in healthy participants.",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT04282746",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Pharmacokinetic study of (S)-ketamine in healthy humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "72ab466ca6435f99b89a959afb9d3b470e17bd597742924833de77f32c523134",
        "title": "The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.",
        "compound": "ketamine",
        "type": "phase_3",
        "institution": "Dr. Inge Winter",
        "condition": "depression",
        "sample_size": 418,
        "status": "recruiting",
        "date": "2024-08-31",
        "abstract": "Over 28 million people suffer from current depressive disorder in the European Union. Major depressive disorder (MDD) is one of the most common psychiatric illnesses. The symptoms cause clinically significant distress or impairment in social, occupational, and other important areas of functioning.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT05973851",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Treatment of major depressive disorder with pharmacological intervention.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "d92db509f66bd74617a3d3c507cdbb94a7a9276aa1a0f4015ba9ee464caf3495",
        "title": "Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL)",
        "compound": "ketamine",
        "type": "phase_1",
        "institution": "South West Sydney Local Health District",
        "condition": "depression",
        "sample_size": 20,
        "status": "recruiting",
        "date": "2025-12-10",
        "abstract": "To assess the safety, feasibility and preliminary efficacy of ketamine-enhanced therapy (KET) for alcohol use disorder (AUD) and comorbid major depressive disorder (MDD) in an open-label, single arm, pilot clinical trial.",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT07247370",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Ketamine for AUD and comorbid depression in a human pilot study.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "c57b6f0b1301cd298c4e9b31745e79b764f0f1d629aaf65610beb9bb9572b44f",
        "title": "Intravenous Ketamine Plus Neurocognitive Training for Depression",
        "compound": "ketamine",
        "type": "phase_1",
        "institution": "Rebecca Price",
        "condition": "depression",
        "sample_size": 154,
        "status": "completed",
        "date": "2017-12-01",
        "abstract": "This study has two aims: 1) to characterize the effects of intravenous ketamine on neurocognitive markers in depressed patients; 2) to test the efficacy of a synergistic intervention for depression combining intravenous ketamine with neurocognitive training.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT03237286",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Ketamine for depression in humans, neurocognitive effects.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "e5b72f1e200f162be4a5d040fdf2fe2a8da752ec97d709c82e249d7a264cb973",
        "title": "Ketamine Treatment Plans for Chronic Conditions",
        "compound": "ketamine",
        "type": "observational",
        "institution": "RIVER Foundation",
        "condition": "depression",
        "sample_size": 500,
        "status": "recruiting",
        "date": "2023-01-01",
        "abstract": "A study aimed to assess the efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the study plan of those with chronic conditions who are receiving ketamine.",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT06038409",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Ketamine for chronic pain and off-label therapeutic use.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "e484be03cd867f1a8045ca82268472b3f21d34a61454d38cb407e8bd18c74ee2",
        "title": "Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder",
        "compound": "ketamine",
        "type": "phase_1",
        "institution": "VA Office of Research and Development",
        "condition": "depression",
        "sample_size": 65,
        "status": "completed",
        "date": "2015-01-01",
        "abstract": "The investigators will compare 3 treatment groups (ketamine plus naltrexone vs. ketamine alone vs. placebo) for treating major depressive disorder (MDD) and alcohol use disorder (AUD) in an 8-week randomized, double-blind, placebo-controlled, between-subjects trial.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT02461927",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Ketamine for depression and alcohol use disorder in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "98f452161a7a1bb9e0d9196950f67ee5460a6f29f15b2bfe4386014c115aa5ce",
        "title": "A Pharmacokinetic, Safety and Tolerability Study of Esketamine in Healthy Elderly and Adult Participants",
        "compound": "ketamine",
        "type": "phase_1",
        "institution": "Janssen Research & Development, LLC",
        "condition": "other",
        "sample_size": 34,
        "status": "completed",
        "date": "2014-03-01",
        "abstract": "The purpose of this study is to compare the pharmacokinetics (explores what the body does to the drug), safety and tolerability of esketamine, administered intranasally (administered through the nose) in healthy elderly (Cohort 1) and healthy adult (Cohort 2) participants.",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT02129088",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Pharmacokinetic, safety, and tolerability study in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "31a769cc4eb92d7e3846b53861570f739b2b8678f0a1715258e7dddb2f815b58",
        "title": "Low-dose S-ketamine in Women With Prenatal Depression",
        "compound": "ketamine",
        "type": "observational",
        "institution": "Peking University First Hospital",
        "condition": "depression",
        "sample_size": 364,
        "status": "completed",
        "date": "2020-06-19",
        "abstract": "Prenatal depression is an important risk factor of postpartum depression. Low-dose ketamine has been used for depression treatment. As a stereoisomer of ketamine, s-ketamine has similar effects to ketamine in anti-depression.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT04414943",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Low-dose S-ketamine for prenatal depression in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "0520e75a61280de8b5a90cff50117e9de0371ffd35ec6babef178858c889bdad",
        "title": "A Single Ketamine Infusion Combined With Music for Suicidal Ideation",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": "The University of Texas Health Science Center at Tyler",
        "condition": "depression",
        "sample_size": 200,
        "status": "active",
        "date": "2021-07-01",
        "abstract": "Suicidal ideation (SI) associated with major and bipolar depression is commonly seen in a wide range of clinical practice situations including the emergency room (ER). Current treatment regimens are often unsatisfactory.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT04658420",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Ketamine for suicidal ideation in depression.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "9bb40d7a76260d699e2539ee7489db56dd7ffd2cb3f582f11aa1bccbd3ae7c82",
        "title": "IV Ketamine vs. IN Esketamine for MDD TRD",
        "compound": "ketamine",
        "type": "observational",
        "institution": "Gustavo Vazquez",
        "condition": "depression",
        "sample_size": 80,
        "status": "recruiting",
        "date": "2023-03-20",
        "abstract": "The goal of this observational study is to learn about the comparative acute effects of ketamine vs esketamine in participants over the age of 18 for the treatment of their severe depression and suicidal ideations.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT06488586",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Observational study of ketamine/esketamine for MDD TRD.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "410b647c371165cc6696464876f87c6c065c41a5f40c9cee46c93d7aaa4bdf7e",
        "title": "Ketamine for the Treatment for Alcohol Use Disorder in the ED",
        "compound": "ketamine",
        "type": "phase_2",
        "institution": "Brigham and Women's Hospital",
        "condition": "addiction",
        "sample_size": 0,
        "status": "completed",
        "date": "2023-09-01",
        "abstract": "The investigators' approach is to conduct a pilot double-blind, placebo-controlled randomized clinical trial with individuals with alcohol use disorder (AUD) seeking inpatient alcohol detoxification in the emergency department (ED) to receive either intravenous ketamine or saline placebo.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT05661669",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Ketamine for alcohol use disorder in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "44272a204967d5278a2d4dc00790db69c67da13c3bf75e91778003bbbe25300d",
        "title": "Electroencephalographic Characteristics of Chronic Pain in Patients With Spinal Cord Injury",
        "compound": "ketamine",
        "type": "observational",
        "institution": "Beijing Tiantan Hospital",
        "condition": "other",
        "sample_size": 60,
        "status": "recruiting",
        "date": "2024-08-25",
        "abstract": "The diagnosis of chronic pain currently lacks objective and quantifiable biomarkers.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT06531837",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Chronic pain is a relevant treatment target.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "83664f1886b15202b67a90574f56cb5602e24c02a71bf03baf40ab1edce4a83d",
        "title": "Netflix exec goes ballistic after being fired for stunning \u2018trust exercise\u2019 confession at retreat: suit",
        "compound": "ketamine",
        "type": "news",
        "institution": "Netflix",
        "condition": "depression",
        "sample_size": null,
        "status": "other",
        "date": "2026-07-27",
        "abstract": "Kevin Baillie, who was vice president and head of creative at Eyeline Studios, is suing the company after they launched an investigation into his comments that ultimately ended in his firing, the papers say.\u2026",
        "outcome_summary": "A Netflix executive was fired after revealing at a work retreat that he had taken medically prescribed ketamine for depression. The company investigated his comments, leading to his termination, and he is now suing for damages.",
        "doi": null,
        "url": "https://nypost.com/2026/07/26/us-news/netflix-exec-goes-ballistic-after-being-fired-for-stunning-trust-exercise-confession-at-retreat-suit/",
        "source": "General News",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Ketamine used for depression, a psychiatric indication.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      }
    ],
    "lsd": [
      {
        "id": "1737542c21cfc81d45bc09d379e5d872fa32e4e095cb03a96304931c4daa7039",
        "title": "Mood Effects of Serotonin Agonists",
        "compound": "lsd",
        "type": "phase_1",
        "institution": "University of Chicago",
        "condition": "other",
        "sample_size": 80,
        "status": "completed",
        "date": "2018-05-01",
        "abstract": "The purpose of this study is to determine the effects of very low doses of serotonergic agonists on depressed mood in human volunteers.",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT03790358",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Serotonin agonists for depressed mood in human volunteers.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "016eba5535847db659689e61ee49762f398ceb5d8a024f65f510e3a15b877fea",
        "title": "The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers",
        "compound": "lsd",
        "type": "observational",
        "institution": "Psychiatric University Hospital, Zurich",
        "condition": "other",
        "sample_size": 25,
        "status": "completed",
        "date": "2015-03-01",
        "abstract": "Aim of the present study is to investigate the neuronal correlates of self and of personal meaning as well as the role of the serotonin (5-HT) 2A receptor system in these processes using functional magnetic resonance imaging (fMRI) and psychometric and cognitive measures.",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT02451072",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Human study on 5-HT2A receptor and self-perception.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      }
    ],
    "dmt": [
      {
        "id": "21da3b3187c3a9095a22422ce54568dd757362170b57d02ba2ab9920b6c928cd",
        "title": "Safety and Pharmacokinetics of GH002 in Healthy Volunteers",
        "compound": "dmt",
        "type": "phase_1",
        "institution": "GH Research Ireland Limited",
        "condition": "other",
        "sample_size": 64,
        "status": "completed",
        "date": "2022-12-22",
        "abstract": "The primary objectives of this study are to investigate the safety and serum pharmacokinetics of 5-MeO-DMT in healthy volunteers in a double-blind, placebo-controlled, randomized study design with single, injected doses of GH002 and in an open-label, non-randomized study design with intra-subject dose-escalation of GH002.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT05753956",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Human study on safety and pharmacokinetics of 5-MeO-DMT.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "c70e0b8b0a78807b033c4a17ab033f83ef88836e8041f6022900f4498addf806",
        "title": "Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects",
        "compound": "dmt",
        "type": "phase_1",
        "institution": "GH Research Ireland Limited",
        "condition": "other",
        "sample_size": 12,
        "status": "recruiting",
        "date": "2026-04-01",
        "abstract": "The primary objectives of this trial are to determine the pharmacokinetic (PK) profile and the safety and tolerability of GH001 delivered via a proprietary aerosol delivery device in healthy subjects after single-dose administration.",
        "outcome_summary": null,
        "doi": null,
        "url": "https://clinicaltrials.gov/study/NCT07540494",
        "source": "ClinicalTrials.gov",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Pharmacokinetics and safety of a novel compound in humans.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      }
    ],
    "ibogaine": [
      {
        "id": "c6310836afc4173ac3a43b63fb497fd6929f68e5b305c9b330dce79a485b5f02",
        "title": "What Is Ibogaine? Trump Admin Fast-Tracks Psychoactive Drug for Approval",
        "compound": "ibogaine",
        "type": "news",
        "institution": null,
        "condition": "addiction",
        "sample_size": null,
        "status": "other",
        "date": "2026-07-24",
        "abstract": "\"There, and especially in Gabon, iboga is regarded as sacred, and is used in the syncretic religion known as Bwiti.\" Unlike better-known psychedelics such as psilocybin, LSD or MDMA, ibogaine is especially associated with addiction treatment.\u2026",
        "outcome_summary": "Ibogaine, a psychoactive compound derived from the Tabernanthe iboga shrub, is being studied as a potential treatment for addiction, PTSD, and depression. While supporters see it as a breakthrough, researchers caution about limited evidence and serious safety risks, including heart problems. The Trump administration is accelerating research and review pathways for ibogaine compounds.",
        "doi": null,
        "url": "https://www.newsweek.com/what-is-ibogaine-trump-admin-fast-tracks-psychoactive-drug-for-approval-12239530",
        "source": "General News",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Ibogaine for addiction, PTSD, depression, and regulatory news.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "d384053c1da254cb98d351fb447b1077c1463522d8e4a78c3e274eff0330ecf7",
        "title": "Trump signs executive order accelerating research into psychedelic drug therapies",
        "compound": "ibogaine",
        "type": "regulatory",
        "institution": null,
        "condition": "other",
        "sample_size": null,
        "status": "other",
        "date": "2026-04-18",
        "abstract": "# Trump signs executive order accelerating research into psychedelic drug therapies The president was joined by RFK Jr., Dr. Oz and Joe Rogan at the White House. ByNicholas Kerr, Liz Neporent, Dr. Jennifer Miao, Dr. Jade Cobern, and Dr.\u2026",
        "outcome_summary": "President Trump signed an executive order to accelerate research and approval of psychedelic-based therapies, particularly ibogaine, for conditions like PTSD, depression, and addiction. The order aims to help veterans with severe mental health issues by providing new treatment options.",
        "doi": null,
        "url": "https://abcnews.com/Health/trump-signs-executive-order-accelerating-research-psychedelic-drug/story?id=132171927",
        "source": "General News",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Executive order on psychedelic therapies for veterans' mental health.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "110fbd313a77dcd8ba5998812870bebd469e9db577f1263091e8b04e48b8d11d",
        "title": "Trump accelerates research on psychedelic treatments and asks, \u2018Can I have some?\u2019",
        "compound": "ibogaine",
        "type": "news",
        "institution": "HHS",
        "condition": "depression",
        "sample_size": null,
        "status": "other",
        "date": "2026-04-18",
        "abstract": "\u00a9 2026 Cable News Network. A Warner Bros. Discovery Company. All Rights Reserved. CNN Sans \u2122 & \u00a9 2016 Cable News Network. ## Download the CNN app Scan the QR code to download the CNN app on Google Play. Scan the QR code to download the CNN app from Google Play.\u2026",
        "outcome_summary": "President Trump signed an executive order to encourage expanded research into psychedelic drugs, including a $50 million investment for ibogaine research. The order aims to accelerate research approval and access to new mental health treatments, potentially moving drug approvals from over a year to weeks.",
        "doi": null,
        "url": "https://www.cnn.com/2026/04/18/politics/trump-signs-executive-order-urging-more-research-into-psychedelic-ibogaine",
        "source": "General News",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Trump accelerates research on psychedelic treatments and asks, \u2018Can I have some?\u2019",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      }
    ],
    "other": [
      {
        "id": "3cf428ef6110c0e5966d9ec98ef0b8e50d21aef14c4eac7579934a3030ea5dbd",
        "title": "Psychedelics Deserve Real Science",
        "compound": "other",
        "type": "news",
        "institution": null,
        "condition": "other",
        "sample_size": null,
        "status": "other",
        "date": "2026-04-22",
        "abstract": "On April 18, 2026, President Donald Trump signed an executive order titled \u201cAccelerating Medical Treatments for Serious Mental Illness.\u201d6 The order directs the FDA to issue National Priority Vouchers for Breakthrough Therapy-designated psychedelics, targets a 1- to 2-month review timeline, creates patient access pathways under the Right to Try Act, and mandates rescheduling on the heels of successful phase 3 trials.\u2026",
        "outcome_summary": null,
        "doi": null,
        "url": "https://www.psychiatrictimes.com/view/psychedelics-deserve-real-science",
        "source": "General News",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Regulatory and policy news regarding psychedelics for mental illness.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      },
      {
        "id": "29592abadbfe681780d0ab684017385105ab28931e6be4a8351d9d580b94a978",
        "title": "How Trump\u2019s executive order could accelerate widespread access to psychedelic therapies",
        "compound": "other",
        "type": "news",
        "institution": null,
        "condition": "other",
        "sample_size": null,
        "status": "other",
        "date": "2026-04-21",
        "abstract": "In recent years, emerging research has shown that psychedelic substances increase neuroplasticity within the brain, allowing the brain to become physically healthier and younger. This phenomenon holds a litany of implications.\u2026",
        "outcome_summary": "President Trump issued an executive order directing federal agencies to accelerate access to psychedelic drugs, including ibogaine, psilocybin, and LSD, as potential treatments for serious mental illnesses. The order aims to expedite FDA reviews for qualifying psychedelic drugs and create pathways for access under the Right to Try Act.",
        "doi": null,
        "url": "https://reason.org/commentary/trumps-executive-order-accelerate-widespread-access-psychedelic-therapies",
        "source": "General News",
        "first_seen": "2026-07-27",
        "relevance": {
          "relevant": true,
          "reason": "Regulatory and policy news on psychedelic therapies for mental illness.",
          "model": "google/gemini-2.5-flash-lite",
          "revision": 2,
          "judged": "2026-07-27"
        }
      }
    ]
  }
}